Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/22/2025 | $44.00 | Buy | BTIG Research |
| 2/4/2025 | $20.00 | Outperform | Wolfe Research |
| 10/11/2024 | $49.00 | Buy | Stifel |
| 10/7/2024 | $45.00 | Buy | H.C. Wainwright |
| 9/17/2024 | $44.00 | Outperform | Leerink Partners |
| 9/16/2024 | Buy | TD Cowen | |
| 9/13/2024 | $40.00 | Buy | Jefferies |
MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka" or the "Company") (NASDAQ:ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $180 million to the Company, before placement agent fees and offering expenses. The PIPE financing was led by Viking Global Investors, and included participation from both new and existing investors, including Affinity Healthc
Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended off-treatment remissions Well tolerated with a favorable safety profile consistent with the IL-23p19 class EVERLAST-A Phase 2a trial enrollment ongoing with data expected 2H 2026 MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced interim data from
First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 trial ongoing, with data to be presented around YE 2025 MENLO PARK, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today reported second quarter 2025 financial results and provided a corporate update. "We are very pleased to have initiated our EVERLAST-A study, and we expect nearl
BTIG Research initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $44.00
Wolfe Research initiated coverage of Oruka Therapeutics with a rating of Outperform and set a new price target of $20.00
Stifel initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $49.00
4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
S-3 - Oruka Therapeutics, Inc. (0000907654) (Filer)
S-3 - Oruka Therapeutics, Inc. (0000907654) (Filer)
424B3 - Oruka Therapeutics, Inc. (0000907654) (Filer)
SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)
SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)
SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)